SLG
XLRN

Stanley-Laman Group’s Acceleron Pharma XLRN Stock Holding History

Stanley-Laman Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-125,020
Closed -$7.16M – 307
2018
Q3 		$7.16M Buy
+125,020
New +$6.14M 1.76% 6

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Stanley-Laman Group's XLRN Position: Q4 2018 in Review

Stanley-Laman Group sold out of Acceleron Pharma (XLRN) in Q4 2018, closing a stake of 125,020 shares — an estimated $7.16M sold.

Stanley-Laman Group first reported a position in XLRN in Q3 2018 and held it in 1 quarter. The position peaked at $7.16M in Q3 2018. 162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • Stanley-Laman Group reported no remaining Acceleron Pharma position as of Q4 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 125,020 Acceleron Pharma shares in Q4 2018, an estimated $7.16M.
  • Stanley-Laman Group first reported a position in Acceleron Pharma in Q3 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Acceleron Pharma position peaked at $7.16M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on Stanley-Laman Group's 13F filing for Q4 2018, filed 7 Feb 2019.